These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 34530847)

  • 21. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromyelitis optica spectrum disorder: pathophysiological approach.
    Mireles-Ramírez MA; Pacheco-Moises FP; González-Usigli HA; Sánchez-Rosales NA; Hernández-Preciado MR; Delgado-Lara DLC; Hernández-Cruz JJ; Ortiz GG
    Int J Neurosci; 2024 Aug; 134(8):826-838. PubMed ID: 36453541
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
    Mader S; Kümpfel T; Meinl E
    Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
    Hinson SR; Lennon VA; Pittock SJ
    Handb Clin Neurol; 2016; 133():377-403. PubMed ID: 27112688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
    Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
    Giglhuber K; Berthele A
    Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Neuromyelitis Optica Spectrum Disorders.
    Chan KH; Lee CY
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
    Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
    Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica].
    Kuroda H; Fujihara K
    Brain Nerve; 2019 Jun; 71(6):573-580. PubMed ID: 31171754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.